Document is current
Any future updates will be listed below
-
Authors
Hebert, Jess D. https://orcid.org/0000-0002-8778-5941
Neal, Joel W. https://orcid.org/0000-0003-3119-9334
Winslow, Monte M. https://orcid.org/0000-0002-5730-9573
- License Information
-
More Information
Article History
Accepted: 27 March 2023
First Online: 3 May 2023
Competing interests
: J.W.N. has received research support from Genentech/Roche, Merck, Novartis, Boehringer Ingelheim, Exelixis, Nektar Therapeutics, Takeda Pharmaceuticals, Adaptimmune, GSK, Janssen and AbbVie; has served in a consulting or advisory role for AstraZeneca, Genentech/Roche, Exelixis, Jounce Therapeutics, Takeda Pharmaceuticals, Eli Lilly and Company, Calithera Biosciences, Amgen, Iovance Biotherapeutics, Blueprint Pharmaceuticals, Regeneron Pharmaceuticals, Natera, Sanofi/Regeneron, D2G Oncology, Surface Oncology, Turning Point Therapeutics, Mirati Therapeutics, Gilead Sciences and AbbVie; and has received honoraria from CME Matters, Clinical Care Options CME, Research to Practice CME, Medscape CME, Biomedical Learning Institute CME, MLI Peerview CME, Prime Oncology CME, Projects in Knowledge CME, Rockpointe CME, MJH Life Sciences CME, Medical Educator Consortium and HMP Education. M.M.W. is a co-founder of and holds equity in D2G Oncology. J.D.H. declares no competing interests.
